neuroendocrine neoplasm

From Aaushi
Jump to navigation Jump to search

Classification

Pathology

distribution of neuroendocrine tumors

* 25% of neuroendocrine neoplasms produce hormones[2]

* most are hormonally non-functioning[2]

Genetics

Clinical manifestations

Laboratory

Radiology

Complications

  • non-functioning tumors may be asymptomatic & develop metastatic disease years before diagnosis

Management

More general terms

More specific terms

References

  1. Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 584
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 Medical Knowledge Self Assessment Program (MKSAP) 16, 17, 18, 19. American College of Physicians, Philadelphia 2012, 2015, 2018, 2021.
    Medical Knowledge Self Assessment Program (MKSAP) 19 Board Basics. An Enhancement to MKSAP19. American College of Physicians, Philadelphia 2022
  3. Reidy DL, Tang LH, Saltz LB. Treatment of advanced disease in patients with well- differentiated neuroendocrine tumors. Nat Clin Pract Oncol. 2009 Mar;6(3):143-52. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19190591
  4. Kulke MH, Siu LL, Tepper JE et al Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011 Mar 1;29(7):934-43. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21263089
  5. 5.0 5.1 5.2 5.3 CPT :accession 81437, 81438
  6. Guidelines:
    2013 NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor. https://www.nanets.net/2013-nanets-guidelines
    The 2016 ENETS Consensus Guidelines for the Diagnosis and Treatment of Neuroendocrine Tumors. http://www.enets.org/current_guidelines.html
    ESMO Clinical Practice Guidelines: Neuroendocrine Tumours. http://www.esmo.org/Guidelines/Neuroendocrine-Tumours
  7. Singh S, Asa SL, Dey C et al Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus. Cancer Treat Rev. 2016 Jun;47:32-45. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27236421
  8. Kaderli RM, Spanjol M, Kollar A et al Therapeutic Options for Neuroendocrine Tumors. A Systematic Review and Network Meta-analysis. JAMA Oncol. Published online February 14, 2019 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30763436 https://jamanetwork.com/journals/jamaoncology/fullarticle/2724799
    Strosberg JR, Al-Toubah T, Cives M Evaluating Risks and Benefits of Evolving Systemic Treatments of Neuroendocrine Tumors. JAMA Oncol. Published online February 14, 2019 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30763444 https://jamanetwork.com/journals/jamaoncology/fullarticle/2724795